Publications by authors named "Eugeny A Gotovkin"
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Douglas E Peterson Nicholas P Barker Lilia I Akhmadullina Irina Rodionova Nailya Z Sherman Eugeny A Gotovkin
J Clin Oncol
September 2009
Article Synopsis
- This study focused on the safety and effectiveness of a topical oral spray containing recombinant human intestinal trefoil factor (rhITF) to prevent and treat chemotherapy-induced oral mucositis (OM) in colorectal cancer patients.
- Ninety-nine patients with moderate to severe OM received either a placebo, low-dose rhITF (10 mg/mL), or high-dose rhITF (80 mg/mL) for 14 days, showing significant reductions in OM incidence (75% to 81%) and severity compared to the placebo group.
- The rhITF oral spray was deemed safe, with only a small percentage of patients reporting mild side effects, and there are plans for future studies to further explore its